TG Therapeutics (TGTX) shares soared on Aug 21 as speculation emerged that the biotech firm could be the target of a potential takeover. Investors cheered TGTX following an “uncooked” alert from Betaville, suggesting a U.S. biopharma company with a market cap between $20 billion and $40 billion may be interested in acquiring TG Therapeutics.
Following the meteoric rally on Friday, TG Therapeutics stock is up about 85% versus the start of this year.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
www.barchart.comWhat We Know About the Takeover News
Investors should note that the Betaville report did not identify the potential buyer, and there’s been no confirmation from TG Therapeutics that takeover discussions are ongoing.
That distinction matters because a takeover rumor can drive a biotech stock higher as investors price in the possibility of an acquisition premium. But those gains can also disappear just as quickly if the speculation is denied or fails to produce a transaction.
That said, TG Therapeutics’ fundamentals nevertheless provide a reason for strategic interest. In Q2, the company’s U.S. revenue from BRIUMVI reached $227.7 million, up a remarkable 64% year-over-year. TGTX subsequently raised its 2026 revenue target to about $950 million.
Should You Chase the Momentum in TGTX Shares?
For disciplined investors, loading up on TG Therapeutics shares purely on takeover rumors appears considerably riskier than buying on confirmed transaction news. There is, however, a legitimate fundamental story underneath the speculation.
BRIUMVI’s rapidly growing sales have driven management to raise its 2026 guidance, while the company remains profitable and continues to invest aggressively in its commercial and pipeline opportunities.
Still, investors should distinguish between the firm’s operating performance and an unconfirmed buyout thesis. Unless a potential suitor emerges or TGTX confirms discussions, Friday’s takeover-driven premium could prove volatile.
For investors who like the underlying business, waiting for the takeover excitement to cool and looking for a more favorable entry may offer a better risk-reward than chasing the momentum on Aug. 21.
How Wall Street Recommends Playing TG Therapeutics Stock
Despite volatility risks, Wall Street remains bullish as ever on TGTX shares for the remainder of 2026.
The consensus rating on TG Therapeutics sits at “Moderate Buy,” with the mean price target of about $64 indicating potential upside of another 17% from here.
www.barchart.com On the date of publication, Wajeeh Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
KeyBanc Just Upgraded Its Price Target on Zscaler Stock. Here's Why. TGTX Stock Alert: What to Know as Takeover Rumors Swirl Around TG Therapeutics Broadcom’s Secret Weapon Against Nvidia Isn’t Chips — It’s a Massive Off-Balance-Sheet Financing Machine Broadcom Stock Just Scored a New Bullish Rating. Here's Why.